MTOR and breast carcinoma: As a matter of fact, blockade of miR-21 in estrogen receptor-alpha positive (ER+) breast cancer lines with miRNA inhibitors leads to higher therapeutical benefits, as seen by induction of autophagic cell death through inhibition of the PI3K-Akt-mTOR pathway (Yu et al., 2016).